News

A new add-on blood test called the FAP-Index may help accurately identify serious liver scarring in people with metabolic dysfunction-associated steatotic liver disease (MASLD),…

Livmarli (maralixibat) successfully cleared rare, debilitating fatty skin growths and eased chronic itching in two young boys with Alagille syndrome in the U.S., according…

Efforts to eliminate new hepatitis C cases by 2030, a goal set by the World Health Organization (WHO), are falling short in high-risk groups,…

Primary sclerosing cholangitis (PSC) patients with inflammatory bowel disease (IBD) face a higher risk of liver-related complications and the need for a liver transplant…

Volixibat, Mirum Pharmaceuticals’ experimental oral treatment, may help reduce circulating bile acids and ease itch in pregnant women with intrahepatic cholestasis of pregnancy…

Daily treatment with Orsobio’s oral candidate TLC-2716 reduces fat levels in both the blood and liver in overweight adults with high blood fat levels…

Infants with cystic biliary atresia (CBA) tend to undergo standard Kasai surgery earlier than those with other forms of biliary atresia, and generally have…

A new test that uses a tiny drop of blood collected from a finger prick and returns results in about an hour can detect…

A noninvasive liver scan used alongside a standard blood test may accurately predict the severity of liver scarring, or fibrosis, in people with primary…

Health Canada has approved Mirum Pharmaceuticals’ oral therapy Livmarli (maralixibat) for cholestatic pruritus — that is, itching due to impaired bile flow —…